Ishita Drugs & Industries Ltd
Incorporated in 1992, Ishita Drugs & Industries
Ltd is engaged in the manufacturing of various APIs and drug intermediates[1]
- Market Cap ₹ 24.2 Cr.
- Current Price ₹ 80.9
- High / Low ₹ 90.8 / 66.0
- Stock P/E 27.2
- Book Value ₹ 37.6
- Dividend Yield 0.00 %
- ROCE 9.91 %
- ROE 8.40 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 0.23% over past five years.
- Company has a low return on equity of 7.64% over last 3 years.
- Earnings include an other income of Rs.0.42 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.34 | 7.54 | 7.10 | 6.44 | 6.90 | 9.09 | 14.83 | 13.95 | 14.09 | 12.07 | 15.19 | 15.00 | 16.17 | |
| 6.89 | 7.23 | 6.82 | 6.08 | 6.45 | 8.57 | 14.07 | 13.03 | 13.01 | 11.31 | 14.28 | 14.01 | 15.22 | |
| Operating Profit | 0.45 | 0.31 | 0.28 | 0.36 | 0.45 | 0.52 | 0.76 | 0.92 | 1.08 | 0.76 | 0.91 | 0.99 | 0.95 |
| OPM % | 6.13% | 4.11% | 3.94% | 5.59% | 6.52% | 5.72% | 5.12% | 6.59% | 7.67% | 6.30% | 5.99% | 6.60% | 5.88% |
| 0.00 | 0.17 | 0.13 | 0.08 | 0.12 | 0.16 | 0.16 | 0.31 | 0.11 | 0.20 | 0.28 | 0.34 | 0.42 | |
| Interest | 0.03 | 0.04 | 0.06 | 0.04 | 0.11 | 0.06 | 0.03 | 0.03 | 0.02 | 0.05 | 0.09 | 0.07 | 0.08 |
| Depreciation | 0.12 | 0.15 | 0.15 | 0.14 | 0.14 | 0.16 | 0.18 | 0.15 | 0.13 | 0.13 | 0.11 | 0.11 | 0.12 |
| Profit before tax | 0.30 | 0.29 | 0.20 | 0.26 | 0.32 | 0.46 | 0.71 | 1.05 | 1.04 | 0.78 | 0.99 | 1.15 | 1.17 |
| Tax % | 33.33% | 24.14% | 30.00% | 30.77% | 25.00% | 26.09% | 23.94% | 20.95% | 23.08% | 25.64% | 24.24% | 25.22% | |
| 0.20 | 0.22 | 0.14 | 0.18 | 0.25 | 0.35 | 0.55 | 0.83 | 0.80 | 0.58 | 0.75 | 0.87 | 0.89 | |
| EPS in Rs | 0.67 | 0.74 | 0.47 | 0.60 | 0.84 | 1.17 | 1.84 | 2.78 | 2.68 | 1.94 | 2.51 | 2.91 | 2.98 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 0% |
| 3 Years: | 2% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 10% |
| 3 Years: | 3% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 22% |
| 3 Years: | 19% |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 8% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves | 2.28 | 2.50 | 2.64 | 2.82 | 3.07 | 3.42 | 3.97 | 4.80 | 5.61 | 6.18 | 6.93 | 7.80 | 8.25 |
| 0.19 | 0.09 | 1.13 | 0.01 | 0.13 | 0.20 | 0.29 | 0.04 | 0.00 | 0.96 | 0.00 | 3.90 | 1.99 | |
| 1.15 | 1.37 | 1.43 | 1.37 | 0.97 | 1.73 | 2.30 | 1.43 | 2.66 | 1.27 | 0.89 | 1.60 | 1.34 | |
| Total Liabilities | 6.61 | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.29 | 14.57 |
| 1.36 | 1.26 | 1.11 | 1.02 | 1.19 | 1.30 | 1.14 | 1.00 | 0.88 | 0.89 | 0.80 | 0.88 | 0.88 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.45 | 1.82 | 2.15 | 2.70 | 3.15 | 4.04 | 5.29 | 3.11 | 4.06 | 3.39 | 3.34 | 3.87 | 6.32 |
| 3.80 | 3.87 | 4.93 | 3.47 | 2.82 | 3.00 | 3.12 | 5.15 | 6.32 | 7.12 | 6.67 | 11.54 | 7.37 | |
| Total Assets | 6.61 | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.29 | 14.57 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.73 | 0.11 | 0.26 | 0.52 | 0.72 | 0.79 | 1.05 | -0.67 | 3.08 | -2.90 | 2.12 | -3.64 | |
| -0.45 | -0.34 | -0.28 | -0.55 | -0.69 | -1.06 | -1.15 | 2.45 | -0.93 | 0.59 | 0.13 | -0.67 | |
| 0.03 | -0.07 | 1.07 | -1.05 | 0.05 | 0.09 | 0.09 | -0.24 | 0.00 | 1.05 | -0.87 | 4.33 | |
| Net Cash Flow | 0.31 | -0.29 | 1.05 | -1.08 | 0.08 | -0.19 | -0.01 | 1.54 | 2.14 | -1.25 | 1.38 | 0.02 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52.21 | 60.51 | 96.65 | 96.35 | 43.38 | 47.38 | 32.24 | 39.77 | 13.99 | 54.43 | 16.82 | 46.23 |
| Inventory Days | 73.00 | 91.60 | 55.65 | 51.49 | 55.56 | 42.20 | 18.49 | 23.06 | 34.81 | 68.22 | 34.27 | 152.28 |
| Days Payable | 69.24 | 78.31 | 91.07 | 108.49 | 43.21 | 78.70 | 60.25 | 34.76 | 73.22 | 36.67 | 14.87 | 32.44 |
| Cash Conversion Cycle | 55.98 | 73.80 | 61.23 | 39.35 | 55.72 | 10.88 | -9.52 | 28.07 | -24.41 | 85.99 | 36.22 | 166.08 |
| Working Capital Days | 57.68 | 64.38 | 10.28 | 56.68 | 32.27 | 8.03 | -10.83 | 29.83 | -27.46 | 42.94 | 21.87 | 30.17 |
| ROCE % | 6.72% | 5.98% | 4.21% | 4.77% | 7.16% | 8.12% | 10.68% | 14.32% | 12.90% | 8.86% | 10.77% | 9.91% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Import reliance for Raw Materials (CIF Basis) Percentage |
|
||||||||||
| R&D Expenditure as % of Turnover Percentage |
|||||||||||
| Number of Permanent Employees Number |
|||||||||||
Documents
Announcements
-
Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations, 2011
27 Feb - Ishita Pharmaceuticals acquired 390 shares (0.01%) on Feb 26, 2026; holding rises to 32,642 (1.09%).
-
Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations, 2011
24 Feb - Ishita Pharmaceuticals bought 506 shares (0.02%), raising holding to 32,252 (1.08%), on Feb 24, 2026.
-
Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations, 2011
19 Feb - Ishita Pharmaceuticals acquired 946 shares (0.03%) on Feb 19, 2026, open market.
-
Disclosure Under Regulation 29(2) Of SEBI (SAST) Regulations, 2011
14 Feb - Ishita Pharmaceuticals acquired 250 shares of Ishita Drugs on Feb 12, 2026; holding now 30,800 shares (1.03%).
- Outcome Of Board Meeting Held On 07Th February, 2026 7 Feb
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
IDIL is a flagship company of Ishita
Group. It is in the business of manufacturing
and sale of Bulk Drugs, Fine Chemicals, and Intermediates. The company supplies
its products to pharmaceutical companies
in India and abroad